BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN - News) today announced its financial results for the third quarter of 2007. For the three months ended September 30, 2007, Enzon reported net income of $87.5 million or $1.23 per diluted share, as compared to net income of $2.2 million or $0.05 per diluted share for the same quarter in 2006. Third quarter results in 2007 were favorably impacted by the August 2007 sale of a 25% interest in future royalties from PEG-INTRON®, marketed by Schering-Plough Corporation, for $92.5 million ($88.7 million net of related costs) to DRI Capital (DRI).
